Page 573 - Williams Hematology ( PDFDrive )

548 Part VI: The Erythrocyte <CN>: <ct> PB

171. Sawada K, Hirokawa M, Fujishima N, et al: Long-term outcome of patients with 183. Chow JK, Chan TK: Low-dose subcutaneous alemtuzumab is a safe and effective treat-
acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nation- ment for chronic acquired pure red cell aplasia. Hong Kong Med J 19(6):549, 2013.
wide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 184. Ahn J, Lee K, Lee J, et al: A case of refractory idiopathic pure red cell aplasia responsive
92(8):1021, 2007. to fludarabine treatment. Br J Haematol 112(2):527, 2001.
172. Yamada O, Mizoguchi H, Oshimi K: Cyclophosphamide therapy for pure red cell 185. Robak T, Kasznicki M, Blonski JZ, et al: Pure red cell aplasia in patients with chronic
aplasia associated with granular lymphocyte-proliferative disorders. Br J Haematol lymphocytic leukaemia treated with cladribine. Br J Haematol 112(4):1083, 2001.
97(2):392, 1997. 186. Messner HA, Fauser AA, Curtis JE, et al: Control of antibody-mediated pure red-cell
173. Go RS, Li CY, Tefferi A, et al: Acquired pure red cell aplasia associated with lymphop- aplasia by plasmapheresis. N Engl J Med 304(22):1334, 1981.
roliferative disease of granular T lymphocytes. Blood 98(2):483, 2001. 187. Freund LG, Hippe E, Strandgaard S, et al: Complete remission in pure red cell aplasia
174. Fujishima N, Sawada K, Hirokawa M, et al: Long-term responses and outcomes fol- after plasmapheresis. Scand J Haematol 35(3):315, 1985.
lowing immunosuppressive therapy in large granular lymphocyte leukemia-associated 188. Hirokawa M, Sawada K, Fujishima N, et al: Long-term response and outcome following
pure red cell aplasia: A Nationwide Cohort Study in Japan for the PRCA Collaborative immunosuppressive therapy in thymoma-associated pure red cell aplasia: A nationwide
Study Group. Haematologica 93(10):1555, 2008. cohort study in Japan by the PRCA collaborative study group. Haematologica 93(1):27,
175. Harris SI, Weinberg JB: Treatment of red cell aplasia with antithymocyte globulin: 2008.
Repeated inductions of complete remissions in two patients. Am J Hematol 20(2):183, 189. Muller BU, Tichelli A, Passweg JR, et al: Successful treatment of refractory acquired
1985. pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Bone Marrow
176. Robak T: Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Transplant 23(11):1205, 1999.
Haematol 72(2):79, 2004. 190. Tseng SB, Lin SF, Chang CS, et al: Successful treatment of acquired pure red cell apla-
177. Sloand EM, Scheinberg P, Maciejewski J, et al: Brief communication: Success- sia (PRCA) by allogeneic peripheral blood stem cell transplantation. Am J Hematol
ful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody 74(4):273, 2003.
(daclizumab). Ann Intern Med 144(3):181, 2006. 191. Kurtzman G, Frickhofen N, Kimball J, et al: Pure red-cell aplasia of 10 years’ duration
178. Ghazal H: Successful treatment of pure red cell aplasia with rituximab in patients with due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.
chronic lymphocytic leukemia. Blood 99(3):1092, 2002. N Engl J Med 321(8):519, 1989.
179. Auner HW, Wolfler A, Beham-Schmid C, et al: Restoration of erythropoiesis by rit- 192. Crabol Y, Terrier B, Rozenberg F, et al: Intravenous immunoglobulin therapy for pure
uximab in an adult patient with primary acquired pure red cell aplasia refractory to red cell aplasia related to human parvovirus b19 infection: A retrospective study of 10
conventional treatment. Br J Haematol 116(3):727, 2002. patients and review of the literature. Clin Infect Dis 56(7):968, 2013.
180. Scaramucci L, Niscola P, Ales M, et al: Pure red cell aplasia associated with hemolytic 193. Kurtzman GJ, Ozawa K, Cohen B, et al: Chronic bone marrow failure due to persistent
anemia refractory to standard measures and resolved by rituximab in an elderly patient. B19 parvovirus infection. N Engl J Med 317(5):287, 1987.
Int J Hematol 88(3):343, 2008. 194. Ramratnam B, Gollerkeri A, Schiffman FJ, et al: Management of persistent B19 parvo-
181. Willis F, Marsh JC, Bevan DH, et al: The effect of treatment with Campath-1H in virus infection in AIDS. Br J Haematol 91(1):90, 1995.
patients with autoimmune cytopenias. Br J Haematol 114(4):891, 2001.
182. Ru X, Liebman HA: Successful treatment of refractory pure red cell aplasia associated
with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtu-
zumab (Campath-1H). Br J Haematol 123(2):278, 2003.

Kaushansky_chapter 36_p0539-0548.indd 548 9/17/15 6:15 PM